Recently, studies report that RABL6 was highly expressed in many cancers, such as non-small cell lung cancer (NSCLC), breast cancer, and pancreatic ductal adenocarcinoma (PDAC), and often related to the poor prognosis for the patients (12–15), which indicated that RABL6 may act as an oncogene to promote cancer progression. Here, RABL6 is linked to pancreatic ductal adenocarcinoma.